This dual mechanism, reduced intake plus increased expenditure, explains why the Phase 2 data showed such dramatically higher weight loss percentages than any dual agonist trial
How Information Resolves Across the Measured Program Pricing clarity arrives in stages, with full cost details spread across intake screens, checkout, and policy terms
It has unique strengths and benefits: Significant A1C reduction and weight loss in Type 2 Diabetes (T2D) patients Safety profile of Orforglipron 3 mg, 12 mg, and 36 mg Tablets is similar to injectable GLP-1 drugs like Mounjaro or Zepbound Orforglipron 3 mg, 12 mg and 36 mg Convenience of daily oral administration It will likely be available in the following doses: Orforglipron 3 mg, 12 mg and 36 mg tablets Orforgliprons Significant A1C Reduction and Weight Loss in ACHIEVE-1 Study Image depicting the action of Orforglipton as a GLP-1 agonist Price: Will most likely vary by country, health system, and insurance status
1 for qualifying obese patients In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter